Sort
10,766 grants matching “checkpoint inhibitor”
Small Molecule Metabolites as Predictors and Mediators of Immune Checkpoint Inhibitor Response
$39,220Ian T. Mathews · La Jolla Institute For Immunology · F31 · FY2019 · CA
Molecular Imaging
$39,215Juri G Gelovani · Wayne State University · P30 · FY2022 · CA
Dissecting the Role of Radiation in Regulation of MHC-I and Neoantigen Presentation
$39,197Chang Su · Duke University · F30 · FY2022 · CA
Identification of a targeted anti-mitotic agent that degrades Myc and specifically induces cancer cell death
$39,112Jessica Teitel · University Of Michigan At Ann Arbor · F31 · FY2022 · CA
Tracking Adoptive T Cell Therapy Using Magnetic Particle Imaging
$39,005Angelie M Rivera-Rodriguez · University Of Florida · F31 · FY2021 · CA
Role of MYC Family Members in Driving Chemoresistance in Small Cell Lung Cancer
$38,976Eli Grunblatt · University Of Washington · F30 · FY2018 · CA
In vivo and in vitro roles played by Hdac3 in genomic stability maintenance
$38,777Srividya Bhaskara · Vanderbilt University · F32 · FY2010 · CA
Endothelial Cell Cycle Control to Normalize the Tumor Vasculature
$38,762Shelby Cain · University Of Virginia · F31 · FY2025 · CA
Defining the functional role of T-cells in Autosomal Dominant Polycystic Kidney Disease pathology
$38,726Katharina Hopp · University Of Colorado Denver · K01 · FY2021 · DK
Advancing Mechanistic Concepts of FGFR1-Regulated Adaptive PDL1 Expression in HNSCC
$38,494Jacqueline Mann · University Of Michigan At Ann Arbor · F31 · FY2018 · DE
Therapeutic and Sustained Cytokine Delivery at the Tumor Site Using Engineered Mononuclear Cells
$38,249Patrick Sean Donahue · Northwestern University · F30 · FY2018 · CA
The role of UV-induced neoantigens and exogenous neoepitopes in enhancing response to immune checkpoint blockade in melanoma and other cancers.
$38,243Mack Su · Harvard Medical School · F30 · FY2018 · ES
Replication control in E. histolytica
$38,231Anindya Dutta · University Of Virginia · R03 · FY2007 · TW
Endothelial Cell Cycle Control to Normalize the Tumor Vasculature
$38,198Shelby Cain · University Of Virginia · F31 · FY2024 · CA
Discovery of myeloid immune features predictive of response to cancer immunotherapy in prostate cancer
$38,188Elizabeth McCarthy · University Of California, San Francisco · F30 · FY2021 · CA
Uncovering actionable signaling pathways required for solid tumor brain metastasis
$38,157Jacob Peter Hoj · Duke University · F99 · FY2019 · CA
Targeted radionuclide therapy for tumor immunomodulation and enhancing immunotherapy response
$38,138Caroline Paula Anne Kerr · University Of Wisconsin-Madison · F30 · FY2023 · CA
Development of PD-L1 Proteolysis-Targeting Chimeras (PROTACs): An Innovative Cancer Drug Discovery Route
$38,073Demonta Coleman · Texas A&M University · F31 · FY2023 · CA
Polyamines drive glioblastoma progression
$37,941Kristen Kay · Cleveland Clinic Lerner Com-Cwru · F31 · FY2022 · CA
NLR and Oral Cancer Immune Escape
$37,819Blake Heath · University Of Michigan At Ann Arbor · F31 · FY2020 · DE
High Throughput/Content Screens for Dynein Inhibitors
$37,812Billy W Day · University Of Pittsburgh At Pittsburgh · R21 · FY2008 · NS
Clinical trial data analysis to design novel treatment regimens in oncology
$37,751Deborah Plana · Harvard Medical School · F30 · FY2021 · CA
Function of the ATR-ATRIP complex
$37,589David K Cortez · Vanderbilt University · R01 · FY2016 · CA
Advancing Mechanistic Concepts of FGFR1-Regulated Adaptive PDL1 Expression in HNSCC
$37,577Jacqueline Mann · University Of Michigan At Ann Arbor · F31 · FY2017 · DE
The Role of SPON1 Expressing Inflammatory Monocytes in Promoting Lung Cancer Metastasis.
$37,543Nisitha Sengottuvel · Univ Of North Carolina Chapel Hill · F30 · FY2021 · CA